Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT-1 in Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT-1 in Healthy Adult Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs LCB10-0200 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Geom Therapeutics
  • Most Recent Events

    • 10 Dec 2018 Status changed from planning to not yet recruiting.
    • 30 May 2018 According to a Geom Therapeutics media release, this trial is expected to begin in 2H of 2018.
    • 30 May 2018 According to a Geom Therapeutics media release, company plans to submit an IND to the FDA in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top